Risperidone-induced hyperamylasemia, hyperlipasemia, and neuroleptic malignant syndrome: a case report.
Ghio
Lucio
L
Fornaro
Gaetano
G
Rossi
Paola
P
D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006801:Humans; D034321:Hyperamylasemia / Q000139:chemically induced* / Q000175:diagnosis / Q000628:therapy; D007273:Injections, Intramuscular; D007441:Intubation, Gastrointestinal; D008049:Lipase / Q000097:blood*; D008140:Lorazepam / Q000008:administration & dosage; D008875:Middle Aged; D009459:Neuroleptic Malignant Syndrome / Q000175:diagnosis / Q000209:etiology* / Q000628:therapy; D010195:Pancreatitis / Q000139:chemically induced* / Q000175:diagnosis / Q000628:therapy; D018967:Risperidone / Q000009:adverse effects*; D012562:Schizophrenia, Disorganized / Q000188:drug therapy*; D016896:Treatment Outcome; D014546:Urinary Catheterization
D014150:Antipsychotic Agents; D008049:Lipase; D018967:Risperidone; D008140:Lorazepam